Pediatric Hodgkin Lymphoma Treated at Cancer Institute, Chennai, India: Long-Term Outcome

Author:

Radhakrishnan Venkatraman1,Dhanushkodi Manikandan1,Ganesan Trivadi S.1,Ganesan Prasanth1,Sundersingh Shirley1,Selvaluxmy Ganesarajah1,Swaminathan Rajaraman1,Rama Ranganathan1,Sagar Tenali Gnana1

Affiliation:

1. All authors: Cancer Institute (WIA), Adyar, Chennai, India.

Abstract

Purpose Pediatric Hodgkin lymphoma (HL) is a highly curable malignancy. Outcomes for pediatric HL may vary between developed and developing countries for multiple reasons. This study was conducted to ascertain the outcomes of children with HL at our center and to identify risk factors for recurrent disease. Methods We analyzed the outcomes of 172 consecutive, previously untreated patients with pediatric HL presenting at our center from 2001 to 2010. Patients were treated with either adriamycin, bleomycin, vinblastine, and dacarbazine or adriamycin, bleomycin, vinblastine, cyclophosphamide, vincristine, prednisone, and procarbazine chemotherapy initially, and radiation to bulky sites or a single site of residual disease when appropriate. Results The median duration of follow-up was 77 months. The median age of the patients was 10 years; 127 (74%) of the 172 patients were male. The extent of disease was stage I and II in 59% of the patients. B symptoms were present in 32% of the patients, and 27% had bulky disease. The most common histologic subtype was mixed cellularity (45%). The 5-year overall survival (OS) and progression-free survival (PFS) of the entire cohort were 92.9% and 83.1%, respectively. The 5-year OS rates for patients with stage I, II, III, and IV were 96%, 94.7%, 84%, and 69.8%, respectively. On univariate analysis, advanced stage, response on interim radiologic assessment, and presence of B symptoms significantly predicted inferior PFS and OS. On multivariate analysis, only interim radiologic response significantly predicted PFS ( P < .001) and OS ( P < .001). Conclusion Overall, the outcomes of patients treated at our center are comparable to those observed in other centers in India and globally.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology,Cancer Research

Reference27 articles.

1. Pizzo PA, Poplack DG: Hodgkin lymphoma, in Pizzo PA and Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 6). Philadelphia, PA, WultersKlower/Lippincott, Williams & Wilkins, 2011, pp 639-662

2. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress report

3. ABVD-Based Therapy for Hodgkin Lymphoma in Children and Adolescents: Lessons Learnt in a Tertiary Care Oncology Center in a Developing Country

4. Hodgkin Lymphoma in Children

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3